Law Offices of Howard G. Smith Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics for allegedly misleading investors regarding the FDA's response to its New Drug Application for relacorilant, leading to significant stock price decline [1][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, with a deadline for lead plaintiff motion set for April 21, 2026 [1]. - The lawsuit claims that Corcept made materially false and misleading statements and failed to disclose adverse facts about its business and prospects during the class period [4]. Group 2: FDA Response and Stock Impact - On December 31, 2025, the FDA issued a Complete Response Letter (CRL) declining to approve Corcept's NDA for relacorilant, stating that additional evidence of effectiveness was required [3]. - Following the FDA's announcement, Corcept's stock price dropped by $35.40 per share, or 50.42%, closing at $34.80 on December 31, 2025 [3]. Group 3: FDA Concerns - An updated CRL published on January 30, 2026, revealed that the FDA had previously expressed concerns about the adequacy of Corcept's clinical development program for relacorilant [4]. - The FDA indicated that significant review issues were expected if Corcept submitted its NDA, which was not disclosed to investors [4].